

controlled substances listed in Schedule II.

The firm planned to import phenylacetone for the production of amphetamine and fentanyl for seed material for the manufacture of fentanyl base.

One registered bulk manufacturer of fentanyl requested a hearing to deny the proposed registration of Noramco Inc., to import fentanyl. Noramco Inc. requested by letter that its application to import fentanyl be withdrawn.

Therefore, Noramco Inc.'s application to import fentanyl is hereby withdrawn.

No comments or objections have been received related to the importation of phenylacetone. DEA has considered the factors in title 21, United States Code, Section 823(a) and determined that the registration of Noramco Inc., is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Noramco Inc., to ensure that the company's registration is consistent with the public interest. The investigations included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to Section 1008(a) of the Controlled Substances Import and Export Act and in accordance with Title 21, Code of Federal Regulations, Section 1301.34, the above firm is granted registration as an importer of the basic class of controlled substance phenylacetone (8501) but their application to import fentanyl (9801) is hereby withdrawn.

Dated: December 4, 2000.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 01-754 Filed 1-9-01; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 25, 2000, Organichem Corporation, 33 Riverside Avenue, Rensselaer, New York 12144, made application by renewal to the Drug Enforcement Administration (DEA) for registration as

a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Amphetamine (1100) .....	II
Methylphenidate (1724) .....	II
Pentobarbital (2270) .....	II
Meperidine (9230) .....	II

The firm plans to manufacture bulk products for distribution to its customers.

Any other such applicants and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than March 12, 2001.

Dated: December 4, 2000.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 01-749 Filed 1-9-01; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 11, 2000, Organix, Inc., 240 Salem Street, Woburn, Massachusetts 01801, made application by renewal of the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer or cocaine (9041), a basis class of controlled substance listed in Schedule II.

The firm plans to manufacture of a derivative of cocaine in gram quantities for validation of synthetic procedures.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR), and must be filed no later than March 12, 2001.

Dated: December 4, 2000.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 01-751 Filed 1-9-01; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the code of Federal Regulations (CFR), this is notice that on October 13, 2000, Orpharm, Inc., 4815 Dacoma Street, Houston, Texas 77092, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Methylphenidate (1724) .....	II
Methadone (9250) .....	II
Methadone-intermediate (9254) ...	II
Levo-alphaacetylmethadol (9648) ..	II

The firm plans to manufacture methadone and methadone-intermediate for production of LAAM, and to manufacture methylphenidate for a customer.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than March 12, 2001.

Dated: December 21, 2000.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 01-755 Filed 1-9-01; 8:45 am]

**BILLING CODE 4410-09-M**